Kairemo Kalevi, Gouda Mohamed, Chuang Hubert H, Macapinlac Homer A, Subbiah Vivek
Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
J Clin Med. 2024 May 31;13(11):3269. doi: 10.3390/jcm13113269.
: The inhibitory effects of tyrosine kinase inhibitors (TKIs) on glucose uptake through their binding to human glucose transporter-1 (GLUT-1) have been well documented. Thus, our research aimed to explore the potential impact of various TKIs of GLUT-1 on the standard [F]FDG-PET monitoring of tumor response in patients. : To achieve this, we conducted an analysis on three patients who were undergoing treatment with different TKIs and harbored actionable alterations. Alongside the assessment of FDG data (including SUVmax, total lesion glycolysis (TLG), and metabolic tumor volume (MTV)), we also examined the changes in tumor sizes through follow-up [F]FDG-PET/CT imaging. Notably, our patients harbored alterations in BRAFV600, RET, and c-KIT and exhibited positive responses to the targeted treatment. : Our analysis revealed that FDG data derived from SUVmax, TLG, and MTV offered quantifiable outcomes that were consistent with the measurements of tumor size. : These findings lend support to the notion that the inhibition of GLUT-1, as a consequence of treatment efficacy, could be indirectly gauged through [F] FDG-PET/CT imaging in cancer patients undergoing TKI therapy.
酪氨酸激酶抑制剂（TKIs）通过与人葡萄糖转运蛋白-1（GLUT-1）结合对葡萄糖摄取的抑制作用已有充分记载。因此，我们的研究旨在探讨GLUT-1的各种TKIs对患者肿瘤反应的标准[F]FDG-PET监测的潜在影响。
为实现这一目标，我们对三名接受不同TKIs治疗且存在可操作改变的患者进行了分析。除了评估FDG数据（包括SUVmax、总病变糖酵解（TLG）和代谢肿瘤体积（MTV））外，我们还通过随访[F]FDG-PET/CT成像检查了肿瘤大小的变化。值得注意的是，我们的患者存在BRAFV600、RET和c-KIT改变，并对靶向治疗表现出阳性反应。
我们的分析表明，源自SUVmax、TLG和MTV的FDG数据提供了与肿瘤大小测量结果一致的可量化结果。
这些发现支持了这样一种观点，即在接受TKI治疗的癌症患者中，由于治疗效果导致的GLUT-1抑制可通过[F]FDG-PET/CT成像间接评估。
